Adverse Outcome Pathways
An adverse outcome pathway (AOP) is structured representation of biological events leading to adverse effects and is considered relevant to risk assessment. The AOP links in a linear way existing knowledge along one or more series of causally connected key events (KE) between two points — a molecular initiating event (MIE) and an adverse outcome (AO) that occur at a level of biological organization relevant to risk assessment. The linkage between the events is described by key event relationships (KER) that describe the causal relationships between the key events. AOPs are important for expanding the use of mechanistic toxicological data for risk assessment and regulatory applications.
- Enzymes
- Anti-Platelet Drugs
- Aspirin
Related Conference of Adverse Outcome Pathways
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
Adverse Outcome Pathways Conference Speakers
Recommended Sessions
- Adverse Outcome Pathways
- Biomarkers in Toxicogenomics
- Cardiovascular Toxicology
- Concept of Toxicogenomics
- Drug monitoring
- Genetic Toxicology
- Genomic Approaches to Predictive Toxicology
- Predictive Human Toxicity and ADME/Tox Studies
- Reproductive and Developmental Toxicology
- Technologies in Toxicogenomics
- Toxicogenomics
- Toxicology study in Haemostasis
- Toxicopathology
Related Journals
Are you interested in
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)

